Objectives To determine whether patients with myasthenia gravis (MG) have serum
antibodies to lipoprotein-related protein 4 (LRP4), a newly identified receptor for agrin that is …

Myasthenia gravis (MG) is an autoimmune disorder characterized by a defect in synaptic
transmission at the neuromuscular junction causing fluctuating muscle weakness with a …

Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction
(NMJ). MG is frequently caused by autoantibodies against acetylcholine receptor (AChR) …

To determine if patients with myasthenia gravis (MG) have antibodies to agrin, a
proteoglycan released by motor neurons and is critical for neuromuscular junction (NMJ) …

Double-seronegative myasthenia gravis (dSN-MG, without detectable AChR and MuSK
antibodies) presents a serious gap in MG diagnosis and understanding. Recently …

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction, where
acetylcholine receptor (AChR), muscle‐specific kinase (MuSK), and low‐density lipoprotein …

Objective: Because the extracellular matrix protein agrin is essential for neuromuscular
junction formation and maintenance, we tested the hypothesis that autoantibodies against …

Introduction Our aim in this study was to identify the prevalence and clinical characteristics of
LRP4/agrin‐antibody–positive double‐seronegative myasthenia gravis (DNMG). Methods …

Objective Amyotrophic lateral sclerosis (ALS) and myasthenia gravis (MG) are caused,
respectively, by motor neuron degeneration and neuromuscular junction (NMJ) dysfunction …

Importance Cell-based assays (CBAs) were shown to improve detection of acetylcholine
receptor (AChR) antibodies in patients with myasthenia gravis (MG). Herein, we asked …